Harvard Bioscience vs Pacific Biosciences of California
HBIO and PACB side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HBIO and PACB compare
Pacific Biosciences of California is the larger company, worth 14 times as much as Harvard Bioscience ($609M against $42.7M).
Pacific Biosciences of California grew revenue faster over the last twelve months (4.4% versus 2.3% for Harvard Bioscience).
Harvard Bioscience keeps more of each dollar of sales as profit, with a net margin of −13.2% compared with −81.3% at Pacific Biosciences of California.
Pacific Biosciences of California scores higher on the StockData Score (4 against 3 for Harvard Bioscience), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HBIO | PACB |
|---|---|---|
| Size and price | ||
| Market cap | $42.7M | $609M |
| Share price | $9.39 | $1.96 |
| Change, 1 year | 50.9% | 12.6% |
| Change, 5 years | −87.4% | −92.6% |
| Beta (5Y) | 1.39 | 2.18 |
| Employees | 339 | 485 |
| StockData Score | ||
| Total score | 3 | 4 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× (better) | 3.8× |
| P/B | 8.4× | – |
| FCF yield | −7.4% (better) | −23.5% |
| Growth | ||
| Revenue growth (TTM) | 2.3% | 4.4% (better) |
| Revenue growth, 5Y average | −3.3% | 15.2% (better) |
| Profitability | ||
| Gross margin | 57.4% (better) | 34.4% |
| Operating margin | −1.8% (better) | −81.3% |
| Net margin | −13.2% (better) | −81.3% |
| FCF margin | −3.5% (better) | −88.8% |
| Return on equity | −123% | – |
| Return on invested capital | −5.6% | – |
| Financial health | ||
| Debt / equity | 7.28 | – |
| Interest coverage | – | −17.2× |
| Current ratio | 1.76 | 4.62 (better) |
| Altman Z-score | −2.36 (better) | −4.92 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 36.9% | 61.5% |
| Held by insiders | – | 4.3% |
| Insider net buying, 12 months | $202K (better) | −$3.4M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 18.1% |
Go deeper
- HBIO stock overview
- HBIO income statement
- HBIO valuation and score
- PACB stock overview
- PACB income statement
- PACB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.